Janus kinase

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024
Well, Janus, International, Neoplasm, Psoriasis, STAT6, Research, Toxicity, AML, Doctor of Philosophy, ASH, Investment, Blood, Atopic dermatitis, Cash, Growth, Janus kinase, Sale, Lupus, Skin, CTCL, PD-1, Inflammation, Society, JAK, Biomarker, Therapy, Immunology, Hidradenitis suppurativa, Administration, Webcast, Inflammatory bowel disease, Patient, Autoimmunity, Arm, Lymphoma, TYK2, Clinical trial, HS, TPD, G&A, Development, Dupilumab, Phase 1, Human, Pharmaceutical industry

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, Health, Janus, Therapy, Key, Inflation, Competitive landscape, Physician, News, Opinion, SWOT, Janus kinase, EU4, Safety, JAK, HTA, Patient, Disease, Drug, Epidemiology, Pharmaceutical industry

The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Janus Kinase (JAK) Inhibitor market report provides insights around existing treatment practices in patients with Janus Kinase (JAK) Inhibitor, approved (if any) and emerging Janus Kinase (JAK) Inhibitor, market share of individual therapies, patient pool eligible for treatment with Janus Kinase (JAK) Inhibitor, along with current and forecasted 7MM Janus Kinase (JAK) Inhibitor market size from 2020-2034 by therapies and by indication.
  • Apart from a comprehensive Janus Kinase (JAK) Inhibitor competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Janus Kinase (JAK) Inhibitor under the late and mid-stage of clinical development for various indications.
  • This section will include details on changing Janus Kinase (JAK) Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Retrieved on: 
Tuesday, January 9, 2024
Well, Janus, STAT3, Patient, Janus kinase, Lymphoma, Therapy, Lupus, ALL, TPD, Asthma, Hematology, STAT6, JAK, Roflumilast, Inflammatory bowel disease, Society, HS, Cancer, Bone marrow, Arm, Q&A, Acute leukemia, IND, MDM2, Autoimmunity, Conference, Interim, Inflammation, TYK2, Psoriasis, Toxicity, Webcast, Clinical trial, File, Atopic dermatitis, Blood, Pharmaceutical industry

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
  • Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
  • KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
  • Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Liver, Marketing, PV, INN, Hypertension, Graft-versus-host disease, Polycythemia, Hydroxycarbamide, Infection, Transplant, Splenomegaly, Bruise, Polycythemia vera, Bacteria, Anatomy, IIA, Spleen, Fever, Hypercholesterolemia, Primary myelofibrosis, ATC, Bleeding, Disease, Ageing, JAK, Neutrophil, Blood, System, Disorder, Weight gain, Enzyme, Safety, Anemia, Sepsis, Medical Subject Headings, Agency, B cell, International, Bone pain, Neutropenia, Language, Mouth, Dizziness, Thrombocytopenia, Pancreatic serous cystadenoma, Hypertriglyceridemia, Tablet, Select, Patient, Medicine, Phlebotomy, Hormone, Woman, Weight loss, Headache, Cytomegalovirus, European Medicines Agency, Growth, Janus kinase, Urinary tract infection, Medical device

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Patient, Medical Subject Headings, Marketing, Cytokine, Protein, Human, INN, Infection, ATC, Pharyngitis, International, Nose, Language, Mouth, CPU socket, Inflammation, JAK, European Medicines Agency, Lower respiratory tract infection, PASI, Tablet, Select, Cell, Diagnosis, Janus kinase, TYK2, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Tuesday, December 19, 2023
Janus, Disease, Tyrosine kinase inhibitor, Dicarboxylic acid, Antibody, Inflammatory bowel disease, B cell, Gastrointestinal disease, Patent, Integrin, Gastrointestinal tract, SAN, Therapy, JAK, GI, IP, Device, Janus kinase, Peptide, United States patent law, Chemokine, Ulcerative colitis, Pharmaceutical industry

SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under development.
  • 17/313,339, entitled “Treatment of a Disease of the Gastrointestinal Tract with a JAK Inhibitor and Devices,” will issue as US Patent No.
  • The patent covers many JAK inhibitors, including those that are approved or in development for a range of indications.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.